We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

Alter Vego

Status: Expired

Apr 13th 2021 - May 14th 2021

Alter Vego (AV) aims to create an extensive range of plant-based, customisable supplements. The company asserts that its production process is sustainable. It starts by creating a vegan protein base blend from ingredients such as pea, hemp, quinoa and brown rice that is ethically sourced and produced. It then develops daily sachets that contain Omega 3, B12, D3, K1, digestive enzymes, and probiotics to complement the base blend. AV argues that the sachets provide 100% of a user's Recommended Dietary Allowance (RDA) over any pre-mixed bulk blend. It aspires to become a contender in the global nutrition sector worth $702 billion. AV will use the investment for manufacturing and marketing its products across the UK.

read more read less

Alter Vego Rating Review

Pitch rating powered by CROWDRATING

Rated on 17/05/2021

Pitch Rated

67%

overall

Management

63%

Product

67%

Investment

70%

Log in to view amount pledged

    Log in to view target

    £1,399,412
    pre-money valuation

    8.50%
    equity available

    102
    investors

    £455
    pledge per investor

    12530924
    company number

    Active
    company status

    23/03/2020
    incorporated 4 years

    £0.28
    share price

    Previous Funding rounds
    18 Apr 24 Crowdcube £46,455 / 36% 66.67%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 63%

Skills 73%
The Alter Vego management team is described as a combination of vision, experience, and execution skills to create a leading plant-based supplement customisation brand. As per the profiles listed publicly and on LinkedIn, the Founder/CEO is a confessed health and wellbeing fanatic and has the ambition to revolutionise the health industry to create sustainable supplements. She is skilled in sustainable business, plant nutrition, logistic management, health and wellness. The Head of Nutrition is a qualified health professional and a registered Nutritional Therapist. She is skilled in nutrition, wellness, public speaking, wellness coaching, health, and fitness. She is the driving force behind the development of Alter Vego’s product range. The Head of Marketing is passionate about boosting brand awareness and customer engagement. She is skilled in creating a brand through media campaign planning, digital strategy, digital marketing, affiliate marketing, social media marketing, display advertising, and optimisation by utilising the web, mobile, and convergence media. The Head of Content is a digital content manager and creative editor with a passion for crafting compelling strategies for brands and publications. She is specialising in creative and original design across all digital channels, from billboards to mobile screens. It was noted that they have not, as yet, appointed a dedicated Finance Head.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £1,399,412
    pre-money valuation

    8.50%
    equity available

    102
    investors

    £455
    pledge per investor

    12530924
    company number

    Active
    company status

    23/03/2020
    incorporated 4 years

    £0.28
    share price

    Previous Funding rounds
    18 Apr 24 Crowdcube £46,455 / 36% 66.67%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph